Australia markets closed

Evoke Pharma, Inc. (EVOK)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.6621-0.0200 (-2.93%)
At close: 04:00PM EST
0.6700 +0.01 (+1.19%)
After hours: 05:22PM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.6821
Open0.6800
Bid0.6600 x 1200
Ask0.6700 x 1100
Day's range0.6412 - 0.7000
52-week range0.6410 - 4.8000
Volume98,950
Avg. volume176,496
Market cap21.622M
Beta (5Y monthly)0.97
PE ratio (TTM)N/A
EPS (TTM)-0.2980
Earnings date10 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est9.00
  • GlobeNewswire

    Evoke Pharma Reports Third Quarter 2021 Financial Results

    SOLANA BEACH, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced its financial results for the quarter ended September 30, 2021 and recent corporate developments. “Through our hard work and valued partnership with Eversana, we continued to increase in-person access to physicians during the third quarter of 2021. We have also successfully executed on str

  • GlobeNewswire

    Evoke Pharma to Report Third Quarter 2021 Financial Results on November 10, 2021

    SOLANA BEACH, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that the Company is scheduled to release its third quarter 2021 financial results on Wednesday, November 10, 2021, after the market closes. Evoke will host a conference call on Wednesday, November 10, 2021, at 4:30 p.m. ET to discuss the results. The dial-in numbers for the conference

  • GlobeNewswire

    Evoke Pharma and EVERSANA Announce Positive Findings from GIMOTI® Market Research Study

    Evoke Pharma, Inc. Trend Across Waves for Proportion of Respondents Who Are Highly Familiar With GIMOTI (score of 4 or 5 out of 5) Health care practitioners’ perception of nasal route of administration similar to IV; 92% intend to prescribe GIMOTI Evoke attending American College of Gastroenterology (ACG) Annual Conference in Las Vegas, October 22-27, 2021 SOLANA BEACH, Calif. and CHICAGO, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company foc